The $110M Bet That CAR-T Can Finally Crack Solid Tumors

Oricell's early data, though, is genuinely encouraging. In a Phase 1 study of 10 patients with advanced HCC, every patient who received the highest dose achieved an objective response, meaning their tumors measurably shrank. One patient hit a complete response (the tumor effectively disappeared) and showed no signs of relapse at nine months.

Ten patients is a tiny study. Nobody should be planning a victory parade. But for a cancer type where CAR-T has historically failed, those numbers are worth watching closely.

Not a One-Trick Pony

Beyond Ori-C101, Oricell has a second program generating buzz. OriCAR-017 targets GPRC5D, a protein found on multiple myeloma cells. It earned FDA IND clearance in January 2024 and has published data in The Lancet Haematology, which is the biotech equivalent of getting your short film into Sundance.

The company also has an in vivo CAR-T program (engineering T-cells directly inside the patient's body, skipping the complex extraction-and-reinfusion process) and a secreting CAR-T called OriC902 designed for hard-to-treat solid tumors. Three proprietary technology platforms power the whole pipeline, including an antibody screening system.

China's CAR-T Gold Rush

Oricell isn't raising money in a vacuum. Chinese biotech is experiencing a funding surge that's hard to ignore. The country's biopharma industry racked up over $60 billion in licensing deals with multinational firms in just the first quarter of 2026, a five-year high for quarterly deal flow.

China now leads the world in CAR-T clinical trial volume, surpassing the U.S. The economics are staggering compared to the West, and that cost advantage has turned China into a global R&D magnet. Companies like Legend Biotech (whose cilta-cel for multiple myeloma is already approved in the U.S. and Europe) have paved the road. Now a new generation of Chinese CAR-T developers, Oricell among them, are following it with even more ambitious targets.

The Elephant in the Room

Of course, geopolitics casts a long shadow over all of this. U.S.-China tensions have complicated cross-border investment and made American stock exchanges less accessible for Chinese biotechs. That's pushed many companies toward Hong Kong's HKEX, which has become the go-to launchpad for Chinese biotech IPOs, with over 400 firms currently queued for listings.

Oricell hasn't said where it plans to list, but the playbook is well-established at this point: raise pre-IPO capital, build a global data package, debut in Hong Kong, and pursue licensing deals with Western pharma giants to access U.S. and European markets.

It's a pragmatic strategy. Big pharma clearly isn't letting political friction stop it from shopping in China's pipeline.

Why You Should Care

The real story here isn't the $110 million. Biotech companies raise money every day. The real story is what happens if Ori-C101 actually works in a pivotal trial.

CAR-T's inability to crack solid tumors has been one of the biggest frustrations in cancer medicine for the past decade. If a Chinese biotech, armed with faster manufacturing, lower trial costs, and early data showing tumors shrinking in liver cancer patients, can break through that barrier? It reshapes the entire competitive landscape.

Oricell is still early. The Phase 1 data is from just 10 patients; the pivotal trials haven't started yet. Plenty of promising cancer therapies have stumbled in larger studies. But the combination of compelling early results, well-funded development, and a massive unmet medical need makes this one worth tracking.

The white whale is still out there. Oricell just bought itself a bigger harpoon.

Neurocrine Just Bet $2.9 Billion on a Disease Most People Have Never Heard Of

Neurocrine Biosciences is spending $2.9 billion to acquire the only approved drug for a rare hunger disorder most people have never heard of. The deal says a lot about where biotech's biggest bets are heading.